• Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust

  • Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust
  1. Home
  2. Cannabis Reclassification

Cannabis Reclassification

Creso Pharma

Creso Pharma’s shares surge following news of Democratic majority in Senate

Finfeed Archived Jan 08, 2021

Following significant share price movement in response to developments in the US, CPH closed at a high of 26.5c, representing a gain of 44% in a mere 24 hours.

Creso Pharma

Positive regulatory ramifications for CPH from US Marijuana Act

Finfeed Archived Dec 07, 2020

Creso Pharma Limited (ASX: CPH; FRA: 1X8) has advised that the US House of Representatives has passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis for the US Controlled Substances Act.

Creso Pharma

United Nations reclassifies cannabis in far-reaching landmark decision

Finfeed Archived Dec 03, 2020

In recognition of the medical benefits of cannabis, a UN Commission has voted to reclassify it to a less restrictive category which could benefit cannabis stocks such as Creso Pharma (ASX: CPH).

Get expert stock analysis direct in your inbox

Join Our
Mailing List

Footer

Portfolio

  • Next Investors
  • Wise Owl
  • Catalyst Hunter
  • Next Biotech
  • Emerge

Support

  • Contact Us
  • Trust Centre
  • How it Works
  • History
  • FAQ
  • Definitions
  • Archived Articles
  • Bottom Drawer Portfolio

Policies

  • Customer Notice
  • Disclosure Policy
  • Financial Services Guide
  • ESG Policy
  • Privacy Policy

Subscribe Next Investors

Daily write ups on small cap stocks we are invested in:


Next Investors

This material has been prepared by S3 Consortium Pty Ltd (trading as StocksDigital). S3 Consortium Pty Ltd is a Corporate Authorised Representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.


© 2026 nextinvestors.com | All rights reserved

Follow Us